Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Biol Sci 2021; 17(13):3381-3400. doi:10.7150/ijbs.62001 This issue Cite

Review

Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells

Sijia Zhang1#, Lingjun Zhan4#, Xue Li1, Zhenhong Yang1, Yumin Luo1,2,3✉, Haiping Zhao1,2✉

1. Institute of Cerebrovascular Disease Research, Xuanwu Hospital of Capital Medical University, Beijing, China.
2. Beijing Geriatric Medical Research Center and National Clinical Research Center for Geriatric Disorders, Beijing, China.
3. Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.
4. Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing, China.
#Co-first authors.

✉ Corresponding authors: Dr. Haiping Zhao, Institute of Cerebrovascular Diseases Research, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Beijing 100053, China. Tel: +86 10 83198129. E-mail: zhaohaipingorg; or to Dr. Yumin More

Citation:
Zhang S, Zhan L, Li X, Yang Z, Luo Y, Zhao H. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells. Int J Biol Sci 2021; 17(13):3381-3400. doi:10.7150/ijbs.62001. https://www.ijbs.com/v17p3381.htm
Other styles

File import instruction

Abstract

Graphic abstract

Genetic changes are difficult to reverse; thus, epigenetic aberrations, including changes in DNA methylation, histone modifications, and noncoding RNAs, with potential reversibility, have attracted attention as pharmaceutical targets. The current paradigm is that histone deacetylases (HDACs) regulate gene expression via deacetylation of histone and nonhistone proteins or by forming corepressor complexes with transcription factors. The emergence of epigenetic tools related to HDACs can be used as diagnostic and therapeutic markers. HDAC inhibitors that block specific or a series of HDACs have proven to be a powerful therapeutic treatment for immune-related diseases. Here, we summarize the various roles of HDACs and HDAC inhibitors in the development and function of innate and adaptive immune cells and their implications for various diseases and therapies.

Keywords: Epigenetics, HDAC, neutrophils, mast cells, macrophage, dendritic cells, lymphocyte, microglia, astrocyte

Citation styles

APA
Zhang, S., Zhan, L., Li, X., Yang, Z., Luo, Y., Zhao, H. (2021). Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells. International Journal of Biological Sciences, 17(13), 3381-3400. https://doi.org/10.7150/ijbs.62001.

ACS
Zhang, S.; Zhan, L.; Li, X.; Yang, Z.; Luo, Y.; Zhao, H. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells. Int. J. Biol. Sci. 2021, 17 (13), 3381-3400. DOI: 10.7150/ijbs.62001.

NLM
Zhang S, Zhan L, Li X, Yang Z, Luo Y, Zhao H. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells. Int J Biol Sci 2021; 17(13):3381-3400. doi:10.7150/ijbs.62001. https://www.ijbs.com/v17p3381.htm

CSE
Zhang S, Zhan L, Li X, Yang Z, Luo Y, Zhao H. 2021. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells. Int J Biol Sci. 17(13):3381-3400.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use